LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Akcijų sąrašas・Design Therapeutics Inc

Design Therapeutics Inc

Uždarymo kaina

15.72 0.83

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

15.31

Max

16.19

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -18M
Pelnas, tenkantis vienai akcijai	-0.29
Darbuotojai	54
EBITDA	-1.5M -20M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+8.9% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	175M 975M
Ankstesnė atidarymo kaina	14.89
Ankstesnė uždarymo kaina	15.72

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

3.26 / 3.63 Palaikymas ir pasipriešinimas

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-12 22:50; UTC

Uždarbis

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

2026-05-12 22:49; UTC

Uždarbis

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

2026-05-12 22:32; UTC

Uždarbis

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

2026-05-12 23:48; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

2026-05-12 22:57; UTC

Rinkos pokalbiai

Uždarbis

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

2026-05-12 22:26; UTC

Uždarbis

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

2026-05-12 22:25; UTC

Uždarbis

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

2026-05-12 22:25; UTC

Uždarbis

Aristocrat Leisure Interim Dividend A$0.50/Security

2026-05-12 22:24; UTC

Uždarbis

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

2026-05-12 22:23; UTC

Uždarbis

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

2026-05-12 22:23; UTC

Uždarbis

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

2026-05-12 22:19; UTC

Uždarbis

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

2026-05-12 22:14; UTC

Uždarbis

CBA: Business Lending Continued to Grow Above System>CBA.AU

2026-05-12 22:14; UTC

Uždarbis

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

2026-05-12 22:13; UTC

Uždarbis

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

2026-05-12 22:12; UTC

Uždarbis

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

2026-05-12 22:12; UTC

Uždarbis

CBA 3Q New Home Loan Funding A$45B>CBA.AU

2026-05-12 22:11; UTC

Uždarbis

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

2026-05-12 22:11; UTC

Uždarbis

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

2026-05-12 22:10; UTC

Uždarbis

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

2026-05-12 22:09; UTC

Uždarbis

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

2026-05-12 22:09; UTC

Uždarbis

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

2026-05-12 22:08; UTC

Uždarbis

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

2026-05-12 22:07; UTC

Uždarbis

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

2026-05-12 22:06; UTC

Uždarbis

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

2026-05-12 22:06; UTC

Uždarbis

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

2026-05-12 22:05; UTC

Uždarbis

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

2026-05-12 22:04; UTC

Uždarbis

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

2026-05-12 22:04; UTC

Uždarbis

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

2026-05-12 22:04; UTC

Uždarbis

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

8.9% į viršų

12 mėnesių prognozė

Vidutinis 17 USD 8.9%

Aukščiausias 21 USD

Žemiausias 14 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Design Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.26 / 3.63Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.